Primary Site >> Pancreatic Cancer
Gene >> PIK3CG
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|
|
Ref: Modulating effect of the PI3-kinase inhibitor LY294002 on cisplatin in human pancreatic cancer cells. PMID: 19032736 |
Ref: Prioritization of driver mutations in pancreatic cancer using cancer-specific high-throughput annotation of somatic mutations (CHASM). PMID: 20581473 |
Ref: Novel agents for the treatment of pancreatic adenocarcinoma. Highlights from the "2011 ASCO Annual Meeting". Chicago, IL, USA; June 3-7, 2011. PMID: 21737890 |
Ref: Phase I study of Rigosertib, an inhibitor of the phosphatidylinositol 3-kinase and Polo-like kinase 1 pathways, combined with gemcitabine in patients with solid tumors and pancreatic cancer. PMID: 22338014 |
Ref: Caffeine and the analog CGS 15943 inhibit cancer cell growth by targeting the phosphoinositide 3-kinase/Akt pathway. PMID: 24521981 Ref: Anticancer activity of HS-527, a novel inhibitor targeting PI3-kinase in human pancreatic cancer cells. PMID: 25016056 Ref: Targeting p110gamma in gastrointestinal cancers: attack on multiple fronts. PMID: 25360116 |
Ref: Modeling targeted inhibition of MEK and PI3 kinase in human pancreatic cancer. PMID: 25376606 |
Ref: Therapeutic Benefit of Selective Inhibition of p110alpha PI3-Kinase in Pancreatic Neuroendocrine Tumors. PMID: 27225693 Ref: Molecular targeted therapy for pancreatic adenocarcinoma: A review of completed and ongoing late phase clinical trials. PMID: 27613577 |
Ref: Clinical significance of Akt2 in advanced pancreatic cancer treated with erlotinib. PMID: 28440469 |
Ref: Notch signaling via regulation of RB and p-AKT but not PIK3CG contributes to MIA PaCa-2 cell growth and migration to affect pancreatic carcinogenesis. PMID: 29434912 |